Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted. The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov. Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

NLM Logo

Brimonidine Tartrate, Timolol Maleate Drug Combination MeSH Descriptor Data 2026


MeSH Heading
Brimonidine Tartrate, Timolol Maleate Drug Combination
Tree Number(s)
D02.033.100.624.915.500
D02.033.755.624.915.500
D02.092.063.624.915.500
D02.886.675.867.768.500
D03.383.129.708.867.768.500
D03.633.100.857.070.500
D26.310.312
Unique ID
D000068599
RDF Unique Identifier
http://id.nlm.nih.gov/mesh/D000068599
Scope Note
A pharmaceutical preparation of brimonidine tartrate and timolol maleate. The combined ADRENERGIC ALPHA2 RECEPTOR AGONIST and ADRENERGIC BETA-ANTAGONIST activity of these drugs reduce INTRAOCULAR PRESSURE in GLAUCOMA patients.
Entry Term(s)
Brimonidine Tartrate-Timolol Maleate
Brimonidine Tartrate-Timolol Maleate Drug Combination
Combigan
Pharm Action
Adrenergic beta-Antagonists
Adrenergic alpha-2 Receptor Agonists
Registry Numbers
0
Public MeSH Note
2016; BRIMONIDINE TARTRATE-TIMOLOL MALEATE DRUG COMBINATION was indexed under QUINOXALINES 2011-2015, under TIMOLOL 2011-2015, and under DRUG COMBINATIONS 2011-2015
History Note
2016 (2011)
Date Introduced
2016/01/01
Last Updated
2016/05/27
Brimonidine Tartrate, Timolol Maleate Drug Combination Preferred
Combigan Narrower
page delivered in 0.151s